ClinicalTrials.gg
RecruitingNCT04664569Updated Apr 28, 2026

National Bacterial Meningitis Study in Children and Newborns

An observational study in Meningitis, Children, Only and Pneumococcal Conjugate Vaccine, sponsored by Association Clinique Thérapeutique Infantile du val de Marne. Recruiting at 1 site in France. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Association Clinique Thérapeutique Infantile du val de Marne · Observational

How we know

From the registry’s dates

  • Started Jan 2001; still recruiting 25 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10,000
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Meningitis with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Meningitis · France.

Started
2001
the only one that year
Observational
8 of 19
2 open now
Registered
14th of 19
by date
Lead sponsor
1 of 19
Association Clinique Thérapeutique Infantile du val de Marne

Among the 19 studies in Meningitis with a site in France, this one is the only one that started in 2001, is one of 8 observational ones, and was the 14th registered.

Meningitis

268 studies on the registry are indexed under Meningitis; 28 are open to participants now.

Browse Meningitis studies →

Open to participants now

3 of the 19 studies in Meningitis with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 17 Meningitis studies recruiting now, 11 (65%) set no upper age limit and 6 (35%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis with a site in France, or all of them as a file.
02

Study summary

Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data. The epidemiology of bacterialméningitis has changed in recent years, mainly owing to widespread use of different conjugate vaccines. The aim of this prospective national survey is to describe epidemiology of bacteria implicated in bacterial meningitis in children.

Read the detailed description

For children under 18, hospitalized for bacterial meningitis, the following data will be analyzed: risk factors, vaccination status, signs of symptoms, treatment during hospitalization, analysis (cerebrospinal fluid culture, cerebrospinal fluid antigen test, blood culture...), symptoms or clinic signs of illness.

03

Conditions studied

  • Meningitis
  • Children, Only
  • Pneumococcal Conjugate Vaccine
  • Meningococcal Vaccines
  • H. Influenzae Vaccine
  • Neonatal Infection
  • Antibiotic Treatment
  • Case Fatality Rate

Browse trials for

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

children 0 day to 18 years with bacterial meningitis or purpura fulminans

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical signs of meningitis, associated with positive cerebrospinal fluid (CSF) culture and/or positive CSF antigen testing (Escherichia coli K1, N. meningitidis serogroups B, A, C, Y and W-135, group B streptococci, Hib, or S. pneumoniae), and/or positive CSF polymerase chain reaction (PCR), and/or positive blood culture with CSF pleocytosis (> 10 cells/µL).
  • purpura fulminans

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. mortality

    Number of death according to age and bacteria

    Time frame: before the hospital discharge

Secondary outcomes

  1. treatment failures

    Number of antibiotic treatment failures according to bacteria after the control of lumbar puncture

    Time frame: 48 hours after the antibiotic treatment and new lumbar puncture

  2. impact of vaccines

    Number of vaccination failures according to age, number of doses and bacteria

    Time frame: before the hospital discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Maunier L, Levy C, Baron A, Weill FX, Bechet S, Pardos de la Gandara M, Caseris M, Abdoul C, Dommergues MA, Cohen R, Bonacorsi S. Retrospective Description of 27 Cases of Nontyphoidal Salmonella Meningitis in Pediatrics Over 22 Years in France Pleads for a Revision of Age Limit for the Treatment of Salmonella Gastroenteritis in Children. Pediatr Infect Dis J. 2026 Jan 1;45(1):e10-e12. doi: 10.1097/INF.0000000000004966. Epub 2025 Sep 3. PubMed 40924727 ↗
  • Fafi I, Cohen R, Levy C, Varon E, Amor-Chelihi L, Benhaim P, Houlier M, Koehl B, De Montalembert M, Allali S, Gauthier A, Odievre MH, Gajdos V, Escoda S, Kamdem A, Costa G, Guillaumat C, Thuret I, Ouldali N, Gaschignard J, Carbonnelle E, De Pontual L, Pham LL. High Mortality Due to Pneumococcal Meningitis in Children With Sickle Cell Disease: A French Multicenter Observational Study From 2001 to 2021. Pediatr Infect Dis J. 2025 Jun 1;44(6):496-502. doi: 10.1097/INF.0000000000004755. Epub 2025 Mar 7. PubMed 40063777 ↗
  • Rybak A, Ouldali N, Varon E, Taha MK, Bonacorsi S, Bechet S, Angoulvant F, Cohen R, Levy C; French Pediatric Meningitis Network. Vaccine-preventable Pediatric Acute Bacterial Meningitis in France: A Time Series Analysis of a 19-Year Prospective National Surveillance Network. Pediatr Infect Dis J. 2024 Jan 1;43(1):74-83. doi: 10.1097/INF.0000000000004134. Epub 2023 Nov 13. PubMed 38108805 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2001 (actual). Primary completion is estimated for Jan 2030, 348 months after the start.

Of 29 observational studies under Meningitis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 96. This study's planned 348 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 11, 2020
StartActual
Jan 1, 2001
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04664569
Lead sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Jan 1, 2001
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Apr 28, 2026

Study contacts

Corinne Levy, MD
Contact
corinne.levy@activ-france.fr
0033148850404
Stephane Bechet
Contact
stephane.bechet@activ-france.fr
1 48 85 96 68 ext. +33
Corinne Levy, MD
study director · Association Clinique Thérapeutique Infantile du val de Marne
Robert Cohen
principal investigator · Association Clinique Thérapeutique Infantile du val de Marne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion